S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
S&P 500   4,438.94 (-0.37%)
DOW   34,891.38 (+0.27%)
QQQ   369.48 (-1.03%)
AAPL   145.07 (-1.26%)
MSFT   293.57 (-1.93%)
FB   351.46 (-0.42%)
GOOGL   2,816.32 (-0.98%)
TSLA   796.48 (+2.85%)
AMZN   3,373.84 (-1.51%)
NVDA   215.76 (-2.29%)
BABA   148.72 (+2.51%)
NIO   36.51 (+3.19%)
CGC   14.65 (+5.32%)
GE   105.90 (+2.02%)
MU   75.28 (+1.66%)
AMD   107.30 (+1.42%)
T   27.55 (+1.55%)
F   14.25 (+3.41%)
ACB   6.35 (+6.72%)
DIS   179.00 (+1.70%)
PFE   43.73 (-0.48%)
BA   226.20 (+2.17%)
BAC   43.34 (+2.85%)
NASDAQ:HRTX

Heron Therapeutics Stock Forecast, Price & News

$12.65
+0.06 (+0.48 %)
(As of 09/27/2021 12:34 PM ET)
Add
Compare
Today's Range
$12.48
$12.87
50-Day Range
$10.13
$13.14
52-Week Range
$10.10
$22.40
Volume10,281 shs
Average Volume1.33 million shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39
30 days | 90 days | 365 days | Advanced Chart
Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Heron Therapeutics logo

About Heron Therapeutics

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
223
Year Founded
N/A

Sales & Book Value

Annual Sales
$88.64 million
Book Value
$2.60 per share

Profitability

Net Income
$-227,280,000.00
Net Margins
-281.99%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.29 billion
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

659th out of 1,352 stocks

Pharmaceutical Preparations Industry

318th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

Is Heron Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Heron Therapeutics stock.
View analyst ratings for Heron Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Heron Therapeutics?

Wall Street analysts have given Heron Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heron Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Heron Therapeutics
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.06. The biotechnology company had revenue of $22.44 million for the quarter, compared to analyst estimates of $28.44 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 107.65% and a negative net margin of 281.99%.
View Heron Therapeutics' earnings history
.

How has Heron Therapeutics' stock price been impacted by COVID-19?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HRTX stock has decreased by 6.6% and is now trading at $12.74.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for HRTX?

3 analysts have issued twelve-month target prices for Heron Therapeutics' shares. Their forecasts range from $24.00 to $27.00. On average, they anticipate Heron Therapeutics' share price to reach $25.33 in the next year. This suggests a possible upside of 98.8% from the stock's current price.
View analysts' price targets for Heron Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:
  • Barry D. Quart, Chairman & Chief Executive Officer
  • John W. Poyhonen, President & Chief Commercial Officer
  • David L. Szekeres, Chief Operating Officer & Executive Vice President
  • Lisa Peraza, VP, Chief Financial & Accounting Officer
  • Thomas B. Ottoboni, Chief Scientific Officer & SVP-Pharmaceutical

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (13.02%), Vanguard Group Inc. (9.15%), BlackRock Inc. (7.39%), ArrowMark Colorado Holdings LLC (5.79%), State Street Corp (4.62%) and JPMorgan Chase & Co. (4.43%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Craig A Johnson, David Leslie Szekeres, John Poyhonen, Kevin C Tang, Kimberly Manhard and Waage Christian.
View institutional ownership trends for Heron Therapeutics
.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., FMR LLC, PFM Health Sciences LP, Bank of America Corp DE, Morgan Stanley, Morgan Stanley, and Alliancebernstein L.P.. Company insiders that have sold Heron Therapeutics company stock in the last year include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard, and Waage Christian.
View insider buying and selling activity for Heron Therapeutics
or view top insider-selling stocks.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Palisade Capital Management LLC NJ, Great Lakes Advisors LLC, Franklin Resources Inc., Balyasny Asset Management LLC, BlackRock Inc., and Kettle Hill Capital Management LLC. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, and Kevin C Tang.
View insider buying and selling activity for Heron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $12.74.

How much money does Heron Therapeutics make?

Heron Therapeutics has a market capitalization of $1.30 billion and generates $88.64 million in revenue each year. The biotechnology company earns $-227,280,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.

How many employees does Heron Therapeutics have?

Heron Therapeutics employs 223 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is www.herontx.com.

Where are Heron Therapeutics' headquarters?

Heron Therapeutics is headquartered at 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 251-4400 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.